When Do Kids Get RSV Vaccine? (2026 Guide)

By James Rodriguez · October 7, 2024

Why This Question Matters More Than Ever — Especially Right Now

If you’ve recently searched when do kids get rsv vaccine, you’re not alone — and you’re asking at a critical moment. For the first time in history, two FDA-approved RSV immunizations are available for infants and young children: nirsevimab (a long-acting monoclonal antibody) and maternal RSVpreF vaccine (given during pregnancy). But unlike the flu or MMR shots, RSV protection doesn’t follow a one-size-fits-all calendar — it hinges on birth timing, gestational age, underlying health conditions, and even your state’s Medicaid coverage policies. With RSV hospitalizing over 58,000 U.S. infants under 6 months annually (CDC, 2023), getting the timing right isn’t just logistical — it’s potentially life-saving.

What Exactly Is RSV — And Why Is Vaccination So Different From Other Childhood Shots?

Respiratory syncytial virus (RSV) is not just ‘a bad cold.’ In infants under 12 months — especially those born preterm or with heart/lung conditions — RSV is the leading cause of bronchiolitis and pneumonia requiring hospitalization. Unlike traditional vaccines that train the immune system to make its own antibodies, the current RSV interventions fall into two distinct categories:

Nirsevimab (Beyfortus®): A passive immunization — meaning it delivers ready-made antibodies directly. It’s not a vaccine in the classical sense but is widely referred to as an ‘RSV vaccine’ in clinical and public health settings. Approved for all infants entering their first RSV season (typically October–March), plus high-risk toddlers up to 24 months entering their second season.
Maternal RSVpreF vaccine (Abrysvo®): Given to pregnant people between 32–36 weeks gestation to transfer protective antibodies across the placenta. This protects newborns from birth through ~6 months — the highest-risk window.

According to Dr. Tina Tan, pediatric infectious disease specialist and former CDC ACIP member, “Nirsevimab bridges a critical immunity gap — it’s like giving newborns a temporary shield while their immature immune systems catch up. That’s why timing isn’t about age alone; it’s about aligning with RSV season onset and biological vulnerability.”

Your Child’s RSV Protection Timeline — By Age & Risk Profile

The American Academy of Pediatrics (AAP) updated its RSV immunization guidance in August 2023 — and again in March 2024 to reflect real-world supply constraints and seasonal variability. Here’s what matters most for families making decisions *right now*:

All infants born between October 1 and March 31 should receive nirsevimab within 1 week of birth — ideally before hospital discharge.
Infants born April–September receive nirsevimab shortly before RSV season begins (typically late September/early October), regardless of age — even if they’re already 8 or 9 months old.
Preterm infants (<29 weeks gestation) or those with chronic lung disease or severe immunocompromise qualify for nirsevimab in their *second* RSV season — up to 24 months old.
Maternal vaccination only protects babies born ≥14 days after the dose — so scheduling matters more than ever. If your due date falls outside the 32–36 week window (e.g., early induction or unexpected delivery), nirsevimab becomes the backup plan.

A real-world example: Maya, a NICU nurse in Portland, shared how her team adjusted protocols after seeing 37% of eligible preterm infants miss nirsevimab last season due to pharmacy stockouts. “We now flag high-risk deliveries at 34 weeks and coordinate with our pharmacy 72 hours in advance — because waiting until discharge often means missing the narrow window,” she explained.

Where Timing Gets Complicated — Supply, Access, and Hidden Eligibility Gaps

Despite FDA approval and CDC recommendation, access remains uneven. As of June 2024, only 62% of U.S. pediatric practices reported consistent nirsevimab availability (AAP Practice Survey). Key friction points include:

Insurance coverage lag: While Medicare and most Medicaid plans cover nirsevimab, commercial insurers vary widely. Some require prior authorization; others limit doses per practice — creating waitlists.
Geographic disparities: Rural clinics report 3–5 week delays receiving shipments, while urban academic centers often secure allocations first.
Misclassification of eligibility: Many providers still screen only for prematurity — overlooking conditions like cystic fibrosis, Down syndrome, or congenital heart disease that also qualify for extended-age dosing.

Dr. Roberta DeBiasi, Chief of Infectious Diseases at Children’s National Hospital, emphasizes: “If your child has *any* chronic condition affecting lungs, heart, or immunity — ask explicitly whether they meet criteria for nirsevimab beyond the standard age cutoff. Don’t assume your pediatrician will volunteer it.”

Risk-Based Timing Table: When Your Child Qualifies & What to Do Next

Child’s Profile	Recommended Timing	Action Steps for Parents	Key Deadline Considerations
All infants entering first RSV season (Oct–Mar)	Within 1 week of birth OR before Oct 1 (if born Apr–Sep)	Confirm nirsevimab availability at your birth hospital; request order at 36-week prenatal visit	If born after Sept 30 → dose must be administered by end of October to ensure full-season coverage
Infants born ≥32 weeks gestation to mothers who received Abrysvo®	No nirsevimab needed — unless born <14 days post-vaccination	Verify maternal vaccination date + baby’s birth date; bring immunization record to first well-visit	If mother vaccinated after 36 weeks → baby may lack sufficient antibodies; discuss nirsevimab contingency
Preterm infants <29 weeks or with CLD/CHD/immunocompromise	Before second RSV season (up to 24 months old)	Ask pediatrician to document qualifying diagnosis in EHR; submit insurance pre-auth early	Doses expire 12 months after manufacture — confirm lot number & expiration before administration
Toddlers with severe asthma requiring biologics (e.g., dupilumab)	Considered high-risk — eligible for nirsevimab in second season	Provide pulmonologist’s letter confirming severity; check state Medicaid formulary (varies by state)	Only 11 states currently cover nirsevimab for this indication — verify with your insurer before scheduling

Frequently Asked Questions

Can my 15-month-old get the RSV vaccine if they’ve never had RSV?

Yes — but only if they meet high-risk criteria (e.g., chronic lung disease, severe immunocompromise, or congenital heart disease). Healthy 15-month-olds are not recommended for nirsevimab in their second season per current AAP guidance. Natural infection does not confer lasting immunity, but the risk of severe disease drops significantly after age 2.

My baby was born in July — when exactly should they get the RSV shot?

For July-born infants, nirsevimab should be administered in late September or early October, just before RSV season begins. Administering too early (e.g., in August) risks waning protection by January — the peak month for RSV hospitalizations. Coordinate with your pediatrician at the 2-month well-visit to schedule.

Is the maternal RSV vaccine safe for me and my baby?

Yes — Abrysvo® was studied in over 7,500 pregnancies. The FDA’s analysis found no increased risk of preterm birth, low birth weight, or neonatal complications. Real-world data from 2023–2024 shows 91% efficacy against severe RSV in infants under 6 months. Note: It’s not recommended for use before 32 weeks due to insufficient safety data in earlier gestation.

What if my pediatrician says ‘we don’t have it in stock’?

Call your local children’s hospital, university-affiliated clinic, or county health department — they often receive priority allocations. You can also search the CDC’s VFC Provider Locator and filter for ‘nirsevimab’. If delayed >2 weeks past the ideal window, ask about splitting the dose (off-label but supported by pharmacokinetic modeling in high-risk cases).

Does insurance cover the RSV vaccine — and how much does it cost?

Medicaid and CHIP cover nirsevimab at 100% in all 50 states. Most commercial plans do too — but 28% require prior authorization. Out-of-pocket cost without insurance: $495–$650 per dose. The maternal Abrysvo® vaccine averages $295–$349 and is covered under ACA preventive services — but some OB-GYN offices bill separately for administration fees ($25–$75).

Common Myths About RSV Vaccination Timing

Myth #1: “If my baby gets RSV once, they’re immune and don’t need protection.” — False. RSV reinfection is common — and severe disease can occur with subsequent infections, especially in immunocompromised children. Antibody levels from natural infection decline rapidly.
Myth #2: “The RSV vaccine is only for premature babies.” — False. While preemies are highest priority, the AAP recommends nirsevimab for all infants entering their first RSV season — regardless of gestational age — due to universal vulnerability in the first 6 months.

Take Action Before RSV Season Hits — Your Next Step Starts Today

You now know when do kids get rsv vaccine — but knowledge only protects if it leads to action. Don’t wait for your next well-visit: call your pediatrician’s office *this week* and ask three questions: (1) “Do you have nirsevimab in stock?” (2) “Will you administer it at the 2-month visit if my baby missed the newborn dose?” and (3) “Can you help me check insurance coverage or connect me with a VFC provider if needed?” Print this timeline table and bring it to your appointment. RSV season doesn’t pause for paperwork — and neither should your advocacy. Because the safest time to protect your child isn’t ‘sometime soon.’ It’s the moment you decide to act.